The companies have entered into a definitive purchase agreement under which Novo Nordisk has acquired Prothena’s clinical stage antibody PRX004 and broader ATTR amyloidosis programme.
PRX004 is a phase 2 ready anti-amyloid immunotherapy designed to deplete the amyloid deposits that are associat